Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,914 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: yokoyama t. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Fujimoto D, et al. Among authors: yokoyama t. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi: 10.1001/jamanetworkopen.2023.0698. JAMA Netw Open. 2023. PMID: 36826813 Free PMC article.
Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: yokoyama t. Lung Cancer. 2023 Dec;186:107426. doi: 10.1016/j.lungcan.2023.107426. Epub 2023 Nov 19. Lung Cancer. 2023. PMID: 37992594
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Shibaki R, Fujimoto D, Miyauchi E, Tsukita Y, Nakachi I, Arai D, Sakata Y, Shingu N, Shimokawa T, Kijima T, Tamiya M, Kawana S, Hara S, Saito G, Sato Y, Yokoyama T, Sakata S, Taniguchi Y, Hata A, Matsumoto H, Yamaguchi T, Yamamoto N. Shibaki R, et al. Among authors: yokoyama t. Lung Cancer. 2024 Oct;196:107958. doi: 10.1016/j.lungcan.2024.107958. Epub 2024 Sep 19. Lung Cancer. 2024. PMID: 39312871 Clinical Trial.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H. Sugisaka J, et al. Among authors: yokoyama t. Lung Cancer. 2024 Dec 9;199:108056. doi: 10.1016/j.lungcan.2024.108056. Online ahead of print. Lung Cancer. 2024. PMID: 39674045
Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Taoka M, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato A, Oda N, Kano H, Nakamura K, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Oze I, Kiura K, Maeda Y, Hotta K. Taoka M, et al. Among authors: yokoyama t. Cancers (Basel). 2024 Dec 6;16(23):4089. doi: 10.3390/cancers16234089. Cancers (Basel). 2024. PMID: 39682275 Free PMC article.
Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y, Saito G, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Junji U, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: yokoyama t. Lung Cancer. 2024 Feb;188:107450. doi: 10.1016/j.lungcan.2023.107450. Epub 2023 Dec 30. Lung Cancer. 2024. PMID: 38160082 No abstract available.
Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study.
Tanaka I, Hori K, Koyama J, Gen S, Morise M, Kodama Y, Matsui A, Miyazawa A, Hase T, Hibino Y, Yokoyama T, Kimura T, Yoshida N, Sato M, Ishii M. Tanaka I, et al. Among authors: yokoyama t. Ther Adv Med Oncol. 2024 Dec 20;16:17588359241303090. doi: 10.1177/17588359241303090. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39712073 Free PMC article.
3,914 results